Po Y. Ho

2.1k citations

17 papers · 1.2k indexed · 1 hit paper · h-index 7

Co-authors: Irving L. Weissman Kelly M. McKenna James Y. Chen Stephen B. Willingham Ying Ying Yiu Nan Ring Aaron M. Ring Sydney Gordon
Topics: Adenosine and Purinergic Signaling (6 papers)Phagocytosis and Immune Regulation (6 papers)Immunotherapy and Immune Responses (6 papers)
Cited by: Immunology Physiology Oncology
Journals: Nature Proceedings of the National Academy of Sciences Nature Communications
Partner nations: United States India Israel

In The Last Decade

Po Y. Ho

15 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy

2017 428 citations Amira Barkal, Kipp Weiskopf et al. Nature Immunology profile →

Peers

Countries citing papers authored by Po Y. Ho

Since Specialization

Citations

This map shows the geographic impact of Po Y. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Po Y. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Po Y. Ho more than expected).

Fields of papers citing papers by Po Y. Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Po Y. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Po Y. Ho. The network helps show where Po Y. Ho may publish in the future.

Co-authorship network of co-authors of Po Y. Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Po Y. Ho. A scholar is included among the top collaborators of Po Y. Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Po Y. Ho. Po Y. Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042 2023 ·Cancer Research ·Justin A. Kenkel,(unknown),Po Y. Ho,(unknown),(unknown),(unknown),(unknown),(unknown),Jason Ptacek,(unknown),Cecelia I. Pearson,(unknown),(unknown),Karla A. Henning,(unknown),Lu Xu,Steven J. Chapin,Michael N. Alonso,Shelley E. Ackerman	1
2	Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance 2021 ·Proceedings of the National Academy of Sciences ·(unknown),Allison Banuelos,Dongdong Feng,(unknown),Kevin S. Kao,Kelly M. McKenna,Stephen B. Willingham,Po Y. Ho,Benyamin Rosental,Michal Caspi Tal,Tal Raveh,Jens-Peter Volkmer,Mark D. Pegram,Irving L. Weissman	95
3	862 Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy 2021 ·Regular and Young Investigator Award Abstracts ·Justin A. Kenkel,Po Y. Ho,Sameera Kongara,Karla A. Henning,(unknown),(unknown),(unknown),Marcin Kowanetz,Michael N. Alonso,Shelley E. Ackerman,Edgar G. Engleman,David Dornan	0
4	605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models 2020 ·SHILAP Revista de lepidopterología ·Heidi Leblanc,Cecelia I. Pearson,Justin A. Kenkel,Lisa K. Blum,Po Y. Ho,Angela Luo,Richard Laura,(unknown),(unknown),(unknown),Shelley E. Ackerman,Brian S. Safina,David Dornan,Michael N. Alonso,Marcin Kowanetz	5
5	603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration 2020 ·SHILAP Revista de lepidopterología ·Shelley E. Ackerman,Felix J. Hartmann,Cecelia I. Pearson,Joseph C. González,Po Y. Ho,Samuel C. Kimmey,(unknown),Benjamin Ackerman,Arthur Lee,Richard Laura,Jason C. Paik,Karla A. Henning,David Jackson,(unknown),Bruce H. Devens,David Dornan,Sean C. Bendall,Edgar G. Engleman,Michael N. Alonso	1
6	A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models 2018 ·Cancer Immunology Research ·Stephen B. Willingham,Po Y. Ho,Andrew Hotson,Craig Hill,Emily Piccione,Jessica Hsieh,Liang Liu,Joseph J. Buggy,Ian McCaffery,Richard A. Miller	162
7	A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer 2017 ·Nature ·Paola Betancur,Brian J. Abraham,Ying Ying Yiu,Stephen B. Willingham,(unknown),Mark A. Zarnegar,Angera H. Kuo,Kelly M. McKenna,Yoko Kojima,Nicholas J. Leeper,Po Y. Ho,Phung Gip,Tomek Swigut,Richard I. Sherwood,Michael F. Clarke,George Somlo,Richard A. Young,Irving L. Weissman	1
8	Abstract 5593: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies 2017 ·Cancer Research ·Stephen B. Willingham,Andrew Hotson,Po Y. Ho,(unknown),Walter Kim,Erik Yusko,Sharon Benzeno,Ginna G. Laport,Richard A. Miller,Ian McCaffery	1
9	A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer 2017 ·Nature Communications ·Paola Betancur,Brian J. Abraham,Ying Ying Yiu,Stephen B. Willingham,(unknown),Mark A. Zarnegar,Angera H. Kuo,Kelly M. McKenna,Yoko Kojima,Nicholas J. Leeper,Po Y. Ho,Phung Gip,Tomek Swigut,Richard I. Sherwood,Michael F. Clarke,George Somlo,Richard A. Young,Irving L. Weissman	178
10	Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapybreakdown → 2017 ·Nature Immunology ·Amira Barkal,Kipp Weiskopf,Kevin S. Kao,Sydney Gordon,Benyamin Rosental,Ying Ying Yiu,Benson M. George,Maxim Markovic,Nan Ring,Jonathan M. Tsai,Kelly M. McKenna,Po Y. Ho,Robin Z. Cheng,James Y. Chen,Layla J. Barkal,Aaron M. Ring,Irving L. Weissman,Roy L. Maute	428
11	Abstract 5598: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models 2017 ·Cancer Research ·Po Y. Ho,(unknown),Andrew Hotson,Richard A. Miller,Ian McCaffery,Stephen B. Willingham	1
12	Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1 2016 ·Annals of Oncology ·Stephen B. Willingham,Po Y. Ho,Robert D. Leone,(unknown),Jonathan D. Powell,Ian McCaffery,Richard A. Miller	2
13	Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy 2016 ·Science Translational Medicine ·Akanksha Chhabra,Aaron M. Ring,Kipp Weiskopf,Peter J. Schnorr,Sydney Gordon,Alan Le,Hye‐Sook Kwon,Nan Ring,Jens Volkmer,Po Y. Ho,Serena Tseng,Irving L. Weissman,Judith A. Shizuru	121
14	Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies 2016 ·Cancer Immunology Research ·Stephen B. Willingham,Andrew Hotson,Po Y. Ho,(unknown),Ginna G. Laport,Ian McCaffery,Richard A. Miller	7
15	Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1 2016 ·Cancer Research ·Stephen B. Willingham,Po Y. Ho,Robert D. Leone,Emily Piccione,(unknown),Andrew Hotson,Joseph J. Buggy,Jonathan D. Powell,Richard A. Miller	4
16	Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk 2015 ·Proceedings of the National Academy of Sciences ·Mingye Feng,James Y. Chen,Rachel Weissman-Tsukamoto,Jens-Peter Volkmer,Po Y. Ho,Kelly M. McKenna,Samuel Cheshier,Michael Zhang,Nan Guo,Phung Gip,Siddhartha S. Mitra,Irving L. Weissman	211
17	HSC transplantation in an immunocompetent host without radiation or chemotherapy 2015 ·Experimental Hematology ·Akanksha Chhabra,Aaron M. Ring,Kipp Weiskopf,Peter J. Schnorr,Sydney Gordon,Alan Le,Hye‐Sook Kwon,Nan Guo,Jens Volkmer,Po Y. Ho,Serena Tseng,Irving L. Weissman,Judith A. Shizuru	2

About Po Y. Ho

Po Y. Ho is a scholar working on Physiology, Immunology and Hematology, having authored 17 papers that have together received 1.2k indexed citations. Recurring topics across this work include Adenosine and Purinergic Signaling (6 papers), Phagocytosis and Immune Regulation (6 papers) and Immunotherapy and Immune Responses (6 papers). The work is most often cited by research in Immunology (855 citations), Physiology (128 citations) and Oncology (391 citations). Po Y. Ho has collaborated with scholars based in United States, India and Israel. Frequent co-authors include Irving L. Weissman, Kelly M. McKenna, James Y. Chen, Stephen B. Willingham, Ying Ying Yiu, Nan Ring, Aaron M. Ring, Sydney Gordon, Kipp Weiskopf and Benyamin Rosental. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact